Medicine and Dentistry
Hematopoietic Stem Cell Transplantation
87%
Graft Versus Host Reaction
75%
Myelodysplastic Syndrome
59%
Aplastic Anemia
52%
Allogeneic Hematopoietic Stem Cell Transplantation
50%
Alemtuzumab
49%
Diseases
43%
Overall Survival
41%
T Cell
34%
Acute Myeloid Leukemia
33%
Secondary Acute Myeloid Leukemia
33%
Acute Leukemia
33%
Acute B-Cell Lymphoblastic Leukemia
33%
Allogeneic Stem Cell Transplantation
33%
Donor Lymphocyte Infusion
24%
Chimeric Antigen Receptor T-Cell
24%
Thymocyte Antibody
22%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Antileukemic Agent
18%
Follicular Lymphoma
16%
Cell Lineage
16%
Hazard Ratio
16%
Pediatrics
16%
Gut
16%
Multiple Sclerosis
16%
Graft Versus Leukemia Effect
16%
Virus Reactivation
16%
Hematopoietic Cell
16%
Cell Transplantation
16%
Epstein Barr Virus
16%
Mycosis
16%
Chronic Graft Versus Host Disease
16%
Cytokine Release Syndrome
14%
Conditioning
14%
Cumulative Incidence
14%
Inflammatory Bowel Disease
13%
Adverse Event
13%
Cytopenia
11%
Recurrence Risk
11%
Calcineurin Inhibitor
11%
Progression Free Survival
11%
Alternative Donor
10%
Stem Cell Transplant
10%
Vedolizumab
10%
Stem Cell
9%
Myeloproliferative Neoplasm
8%
Chronic Myelomonocytic Leukemia
8%
Fludarabine
7%
Integrin
6%
Calgranulin
6%
Immunology and Microbiology
Alemtuzumab
100%
Graft-Versus-Host Disease
99%
Aplastic Anemia
90%
Allogeneic Hematopoietic Stem Cell Transplantation
80%
Hematopoietic Stem Cell Transplantation
78%
Overall Survival
63%
Conditioning
52%
T Cell
50%
Chronic Graft Versus Host Disease
47%
Allogeneic Stem Cell Transplantation
33%
Cyclophosphamide
28%
Lymphocyte
25%
Anti-Thymocyte Globulin
22%
Myeloid
22%
Cytotoxic T-Cell
16%
B Cell
16%
Cell Lineage
16%
Cell Transplantation
16%
Hematopoietic Cell
16%
Inflammatory Bowel Disease
16%
Chimeric Antigen Receptor T-Cell
16%
CD19
16%
Epstein Barr Virus
16%
Virus Reactivation
16%
Multiple Sclerosis
16%
Vedolizumab
12%
CXCR3
12%
Stem Cell Transplant
11%
Stem Cell
11%
CD4
10%
Cytokine Release Syndrome
10%
Event Free Survival
10%
CD3 Antigen
8%
Integrin
8%
Viral Disease
7%
Disease Free Survival
5%
Methotrexate
5%
Human Leukocyte Antigen
5%
Immunosuppressive Therapy
5%
Acute Graft Versus Host Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
79%
Aplastic Anemia
67%
Acute Lymphoblastic Leukemia
33%
Chimeric Antigen Receptor
33%
Fludarabine
31%
Cyclophosphamide
30%
Graft Versus Host Reaction
27%
Overall Survival
26%
Chronic Graft Versus Host Disease
26%
Thymocyte Antibody
20%
Diseases
17%
Myelodysplastic Syndrome
16%
CD8 Antigen
16%
Acute Myeloid Leukemia
16%
Myelofibrosis
16%
Multiple Sclerosis
16%
Epstein-Barr Virus
16%
Antileukemic Agent
16%
Cytokine Release Syndrome
13%
Adverse Event
11%
Cytopenia
10%
Progression Free Survival
7%
Virus Infection
6%
Immunosuppressive Agent
6%
Remission
5%
Janus Kinase
5%
Retrospective Study
5%
